TY - JOUR
T1 - Preliminary study of the treatment of nephrolithiasis (calcium stones) with diphosphonate
AU - Ohata, Masahiro
AU - Pak, Charles Y C
N1 - Funding Information:
From the Department of Internal Medicine. Southwestern Texas Health Science Center at Dallas, Dallas, Texas. Receivedfor publication June 14, 1974. Supported bv a grant from Proctor and Gamble Company and bv USPHS 16061 and I-MOI-RR00633. Reprinr requesrs should be addressed to Dr. Charles Y. C. Pak, General Clinical ter. Southwestern Medical School. The Universiry of Texas Healrh Science Center. 75235. ~1 1974 by Grune & Srrairon. Inc.
PY - 1974/12
Y1 - 1974/12
N2 - Eight patients with absorptive hypercalciuria and renal stones received disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP) orally at dosages ranging from 5 to 20 mg/kg/day. Examination of their urine revealed a marked inhibition of crystal growth of brushite, the nidus for certain renal stones, coincident with the appearance in urine of EHDP. In three cases, there was an inhibition of nucleation of brushite as well. Except for a transient rise in serum alkaline phosphatase activity and a slight increase in urinary cyclic AMP, no significant side effects have been encountered. Intestinal calcium absorption and bone density did not change significantly during 6 mo of treatment. EHDP may therefore be clinically useful in the prevention of the formation of renal stones of calcium phosphate origin.
AB - Eight patients with absorptive hypercalciuria and renal stones received disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP) orally at dosages ranging from 5 to 20 mg/kg/day. Examination of their urine revealed a marked inhibition of crystal growth of brushite, the nidus for certain renal stones, coincident with the appearance in urine of EHDP. In three cases, there was an inhibition of nucleation of brushite as well. Except for a transient rise in serum alkaline phosphatase activity and a slight increase in urinary cyclic AMP, no significant side effects have been encountered. Intestinal calcium absorption and bone density did not change significantly during 6 mo of treatment. EHDP may therefore be clinically useful in the prevention of the formation of renal stones of calcium phosphate origin.
UR - http://www.scopus.com/inward/record.url?scp=0016289281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016289281&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(74)90033-X
DO - 10.1016/0026-0495(74)90033-X
M3 - Article
C2 - 4372511
AN - SCOPUS:0016289281
VL - 23
SP - 1167
EP - 1173
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 12
ER -